Galena Biopharma In The News
- Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC
- Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
- Galena Biopharma to Present at the Stifel 2014 Healthcare Conference
- Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients
Galena is committed to ensuring eligible patients have access to our products. Learn more at GalenaPatientServices.com.